Prediction of Adverse Pregnancy Outcome Related to Placental Dysfunction Using the sFlt-1/PlGF Ratio: A Narrative Review

被引:8
|
作者
Graupner, Oliver [1 ,2 ]
Enzensberger, Christian [1 ]
机构
[1] RWTH Univ, Univ Hosp Aachen, Dept Obstet & Gynecol, Pauwelsstr 30, D-52074 Aachen, Germany
[2] Tech Univ, Univ Hosp Rechts Isar, Dept Obstet & Gynecol, Munich, Germany
关键词
(anti-)angiogenic factors; placental growth factor; soluble fms-like tyrosine kinase 1; preeclampsia; fetal growth restriction; adverse perinatal outcome; (anti-)angiogene Faktoren; plazentarer Wachstumsfaktor; losliche Fms-ahnliche Tyrosinkinase 1; Praeklampsie; fetale Wachstumsrestriktion; ungunstiges perinatales Outcome; FETAL-GROWTH RESTRICTION; ANGIOGENIC FACTORS; PERINATAL OUTCOMES; TYROSINE KINASE-1; WOMEN; PREECLAMPSIA; DOPPLER; RISK; SURVEILLANCE; ULTRASOUND;
D O I
10.1055/a-1403-2576
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio is a helpful tool for the prediction and diagnosis of preeclampsia (PE). Current data even show that the ratio has the potential to predict adverse pregnancy outcomes (APO) caused by placental pathologies. The aim of this article is to give a brief overview of recent findings on APO predictions based on the sFlt-1/PlGF ratio. The focus is on obstetric pathologies related to placental dysfunction (PD) such as PE and/or fetal growth restriction (FGR). New uses of the sFlt-1/PlGF ratio as a predictor of APO demonstrate its potential with regard to planning hospitalization and corticosteroid administration and the optimal timing of delivery. However, prospective interventional studies are warranted to define the exact role of the sFlt-1/PlGF ratio as a predictor of adverse pregnancy outcomes caused by placental pathologies. Zusammenfassung Der sFlt-1-(losliche Fms-ahnliche Tyrosinkinase-1)/PlGF-(plazentarer Wachstumsfaktor-)Quotient ist ein nutzliches Werkzeug fur die Prognose und Diagnose einer Praeklampsie (PE). Aktuelle Daten zeigen sogar, dass der Quotient das Potenzial hat, durch plazentare Pathologien hervorgerufene ungunstige perinatale Outcomes (APO) vorherzusagen. Dieser Artikel gibt einen kurzen uberblick uber die neuesten Erkenntnisse zu APO-Vorhersagen, die auf dem Einsatz des sFlt-1/PlGF-Quotienten basieren. Im Mittelpunkt stehen geburtshifliche Pathologien, die durch eine plazentare Dysfunktion (PD) wie PE und/oder fetale Wachstumsrestriktion (FGR) hervorgerufen werden. Neue Einsatzfelder fur den sFlt-1/PlGF-Quotienten als Pradiktor von APO zeigen sein Potenzial bei der Planung einer Einweisung ins Krankenhaus bzw. der Verabreichung von Kortikosteroiden sowie fur die optimale Terminierung einer Entbindung. Prospektive interventionelle Studien sind notwendig, um die prazise Rolle des sFlt-1/PlGF-Quotienten als Pradiktor von ungunstigen Schwangerschaftsergebnissen, die durch plazentare Pathologien hervorgerufen werden, zu ermitteln.
引用
收藏
页码:948 / 954
页数:7
相关论文
共 50 条
  • [31] Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia
    Verlohren, Stefan
    Brennecke, Shaun P.
    Galindo, Alberto
    Karumanchi, S. Ananth
    Mirkovic, Ljiljana B.
    Schlembach, Dietmar
    Stepan, Holger
    Vatish, Manu
    Zeisler, Harald
    Rana, Sarosh
    PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2022, 27 : 42 - 50
  • [32] Role of sFlt-1/PlGF ratio in predicting clinical outcome in pre-eclampsia
    Chatterjee, Arpan
    Mahmood, Nargis
    Rajasri, Aylur G.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 50 - 50
  • [33] Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia
    Lecarpentier, Edouard.
    Vieillefosse, Sarah
    Haddad, Bassam
    Fournier, Thierry
    Leguy, Marie-Clemence
    Guibourdenche, Jean
    Tsatsaris, Vassilis
    ANNALES DE BIOLOGIE CLINIQUE, 2016, 74 (03) : 259 - 267
  • [34] Predicting Preeclampsia in Gestational Diabetes Mellitus Using the sFlt-1/PlGF Ratio
    Noonan, Sarah Brittany
    Brennecke, Shaun Patrick
    Jones, Gabriel Davis
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
  • [35] Diagnostic value of sFlt-1/PlGF-1 ratio and plasma PROK1 for adverse pregnancy outcomes in women with hypertensive disease of pregnancy
    Lv, Ping
    Lu, Lin-Fei
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2024, 40 (12): : 1068 - 1076
  • [36] Ultrasonographic Findings of Fetal Cardiac Parameters Related to sFlt-1/PlGF Ratio.
    Mori, Kohei
    Hamada, Hirotaka
    Izumi, Seiya
    Takahashi, Tsukasa
    Saito, Shoko
    Tomita, Hasumi
    Tadakawa, Mari
    Iwama, Noriyuki
    Masatoshi, Saito
    REPRODUCTIVE SCIENCES, 2024, 31 : 176A - 177A
  • [37] THE ADDED VALUE OF THE BIOMARKERS SFLT-1, PLGF AND THEIR RATIO ON PREDICTION OF PROLONGATION OF PREGNANCY AND MATERNAL AND FOETAL COMPLICATIONS IN (SUSPECTED) PREECLAMPSIA
    Saleh, L.
    Vergouwe, Y.
    Danser, A. H. J.
    Verdonk, K.
    Steegers, E. A. P.
    Russcher, H.
    Van den Meiracker, A. H.
    Visser, W.
    JOURNAL OF HYPERTENSION, 2017, 35 : E177 - E177
  • [38] sFlt-1, Not PlGF, Is Related to Twin Gestation Choronicity in the First and Third Trimesters of Pregnancy
    Kozlowski, Szymon
    Stelmaszczyk-Emmel, Anna
    Szymusik, Iwona
    Saletra-Bielinska, Aleksandra
    Brawura-Biskupski-Samaha, Robert
    Pietruski, Pawel
    Osinska, Agnieszka
    Kosinska-Kaczynska, Katarzyna
    DIAGNOSTICS, 2021, 11 (07)
  • [39] Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia
    Graupner, Oliver
    Karge, Anne
    Flechsenhar, Sarah
    Seiler, Alina
    Haller, Bernhard
    Ortiz, Javier U.
    Lobmaier, Silvia M.
    Axt-Fliedner, Roland
    Enzensberger, Christian
    Abel, Kathrin
    Kuschel, Bettina
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2020, 301 (02) : 375 - 385
  • [40] Predictive value of the sFlt-1/PlGF ratio in women with suspected preeclampsia: An update (Review)
    Velegrakis, Alexandros
    Kouvidi, Elisavet
    Fragkiadaki, Persefoni
    Sifakis, Stavros
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2023, 52 (04)